CLINICAL SCIENCE

Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory, and artificial intelligence–radiological differences

Piero Ruscitti,1 Federico Bruno,1 Onorina Berardicurti1, Chiara Acanfora,1 Viktoriya Pavlych,1 Pierpaolo Palumbo,1 Alessandro Conforti,1 Francesco Carubbi1,2 Ileneia Di Cola,1 Paola Di Benedetto,1 Paola Cipriani,1 Davide Grassi,3 Carlo Masciocchi,1 Annamaria Iagnocco,4 Antonio Barile,1 Roberto Giacomelli1

Handling editor Josef S Smolen

Abstract

Objectives To evaluate the clinical pictures, laboratory tests and imaging of patients with lung involvement, either from severe COVID-19 or macrophage activation syndrome (MAS), in order to assess how similar these two diseases are.

Methods The present work has been designed as a cross-sectional single-centre study to compare characteristics of patients with lung involvement either from MAS or severe COVID-19. Chest CT scans were assessed by using an artificial intelligence (AI)-based software.

Results Ten patients with MAS and 47 patients with severe COVID-19 with lung involvement were assessed. Although all patients showed fever and dyspnoea, patients with MAS were characterised by thrombocytopenia, whereas patients with severe COVID-19 were characterised by lymphopaenia and neutrophilia. Higher values of H-score characterised patients with MAS when compared with severe COVID-19. AI-reconstructed images of chest CT scan showed that apical, basal, peripheral and bilateral distributions of GGOs, as well as apical consolidations, were more represented in severe COVID-19 than in MAS. C reactive protein directly correlated with GGOs extension in both diseases, whereas lymphopaenia inversely correlated with GGOs extension in severe COVID-19.

Conclusions Our data could suggest laboratory and radiological differences between MAS and severe COVID-19, paving the way for further hypotheses to be investigated in future confirmatory studies.

Key messages

What is already known about this subject?

- Severe COVID-19 and macrophage activation syndrome (MAS) are challenging disorders characterised by overlapping clinical pictures, and it is still matter of debate if severe COVID-19 is part or not of the haemophagocytic lymphohistiocytosis spectrum.

What does this study add?

- Although all patients showed fever and dyspnoea, MAS patients were characterised by thrombocytopenia and higher H-score, whereas severe COVID-19 patients were characterised by lymphopaenia and neutrophilia.

- Artificial intelligence (AI)-reconstructed images of chest CT scan showed that apical, basal, peripheral and bilateral distributions of GGOs, as well as apical consolidations, were more represented in severe COVID-19 than in MAS.

- C reactive protein directly correlated with GGOs extension in both diseases, whereas lymphopaenia inversely correlated with GGOs extension in severe COVID-19.

How might this impact on clinical practice or future developments?

- Laboratory and AI–radiological differences have been shown between MAS and severe COVID-19, thus helping physicians to differentiate these patients in spite of overlapping clinical pictures.

Introduction

The COVID-19 pandemic has brought attention to a virally induced hyperinflammatory lung injury, sometimes evolving to multiple-organ failure and death.1 This finding mirrors what has been observed in macrophage activation syndrome (MAS),2 a secondary form of haemophagocytic lymphohistiocytosis (HLH), complicating rheumatic diseases, mostly adult-onset Still’s disease (AOSD), rapidly evolving into multiple-organ failure and death in a large percentage of patients.4 5 Recently, during AOSD and its juvenile counterpart, pulmonary involvement has been strictly associated with MAS and poor outcome.6 7 Thus, the analysis of chest CT associated with artificial intelligence (AI) tools may be of crucial importance to assess these patients.8 9

A scientific debate is being raised about the possibility that severe COVID-19 may be considered part of the HLH spectrum due to overlapping clinical features.10 11 To assess how similar these two diseases are, we evaluated the clinical pictures,
laboratory tests and AI imaging of patients with lung involvement, either from COVID-19 or MAS. Finally, we correlated the specific laboratory abnormalities observed in our patients with the extension of lung involvement.

**PATIENTS AND METHODS**

**Study design, setting and patients**

The present work has been designed as a cross-sectional single-centre study to compare clinical, laboratory and AI–radiological findings between patients with lung involvement either from MAS or severe COVID-19. Patients with MAS, diagnosed by previous criteria, were retrospectively selected from our database. Their underlying disease was AOSD, diagnosed according to Yamaguchi criteria, without documented lung involvement, and treated with glucocorticoids, 0.2–0.3 mg/kg/day of prednisone equivalent and non-steroidal anti-inflammatory drugs, on-demand, during acute flares. MAS was triggered in all patients by a new acute AOSD flare, in the context of a polycyclic disease pattern. Patients with MAS were matched with consecutive patients with severe COVID-19 attending our institution and admitted to intensive or subintensive care units (online supplementary figure S1 and table S1). All patients with severe COVID-19 showed severe acute respiratory syndrome coronavirus 2 infection confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR). Pulmonary and other infections were excluded in both groups by a specific diagnostic workup including blood cultures, bone marrow cultures, serology, RT-PCR analyses, chest X-rays, chest CT scan, and heart and abdominal echographies. All data were collected before starting any immunosuppressive therapy for MAS or severe COVID-19. Informed consent was obtained from each patient for the use of clinical and laboratory data for study purposes. In reporting the results, we followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines (online supplementary table S2).

**Variables to be assessed, image acquisition and analysis**

CT examinations were performed using a multidetector CT scanner with a single spiral acquisition obtained from the apex to the base of the lungs, with the patient in supine position at full inspiration. Scanning parameters were as follows: 250–330 mm field of view (FOV), 512×512 matrix, 120 kV, 100–150 mAs and tube rotation time of 0.5/0.3 ms. Two radiologists, unaware of the underlying diagnoses, independently reviewed all CT examinations, with final conclusions reached by consensus. Images were reviewed using lung parenchyma (level, −600 to −700 HU; width, 1200–1500 HU) and mediastinal (level, 20–50 HU; width, 350–400 HU) window settings. Presence and distribution of lung parenchymal abnormalities were assessed according to the glossary of terms for thoracic imaging by the Fleischner Society, as reported in table 1 and online supplementary table S3. An AI-based software (Myrian V2.0, Intrasense, France) was used to obtain quantitative data about lung abnormalities.

**Table 1 Laboratory findings in patients with MAS and COVID-19**

| Laboratory findings | MAS | COVID-19 | P value |
|---------------------|-----|----------|---------|
| CRP, mean±SD (mg/L) | 129.7±26.58 | 111.93±14.24 | 0.564 |
| Ferritin, mean±SD (ng/mL) | 4888.83±1131.49 | 1207.17±171.66 | 0.010 |
| Red blood cells, mean±SD (10^9/L) | 4.01±0.28 | 4.58±0.23 | 0.092 |
| Haemoglobin, mean±SD, (g/dL) | 9.5±1.8 | 12.5±2.1 | <0.0001 |
| Platelets, mean±SD (10^11/L) | 121.90±36.34 | 254.53±19.51 | 0.043 |
| Neutrophils, mean±SD (10^9/mL) | 4.08±0.55 | 8.98±2.32 | 0.044 |
| Lymphocytes, mean±SD (10^9/mL) | 2.61±0.58 | 1.02±0.9 | 0.005 |
| Monocytes, mean±SD (10^9/mL) | 0.32±0.09 | 0.55±0.05 | 0.063 |
| D-dimer>4 ng/mL, n (%) | 4 (40%) | 10 (21.27%) | 0.076 |
| D-dimer, mean±SD (ng/mL) | 3.2±0.9 | 2.9±1.4 | 0.069 |
| Fibrinogen, mean±SD (mg/dL) | 386.6±121.4 | 534.3±177.9 | 0.031 |
| pTTP, mean±SD (s) | 37.7±2.2 | 33.8±4.9 | 0.020 |
| INR, mean±SD | 1.7±1.1 | 1.2±0.5 | 0.206 |
| AST, mean±SD (IU/L) | 148.8±75.2 | 34.7±13.1 | 0.002 |
| ALT, mean±SD (IU/L) | 178.9±77.4 | 42.4±14.8 | 0.001 |
| CK, mean±SD (IU/L) | 105.2±58.9 | 133.3±51.9 | 0.605 |
| Albumin, mean±SD (g/dL) | 2.97±0.7 | 3.25±0.8 | 0.351 |
| BNP, mean±SD (pg/mL) | 100.9±40.1 | 170.3±65.2 | 0.585 |
| Troponin I, mean±SD (ng/L) | 11.8±3.2 | 24.1±11.9 | 0.164 |

Bolded values indicate statistically significant results.

ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BNP, brain natriuretic peptide; CK, creatine kinase; COVID-19, coronavirus disease 2019; CRP, C reactive protein; INR, international normalised ratio; MAS, macrophage activation syndrome.

**Table 2 Chest CT scan findings in patients with MAS and COVID-19**

| Chest CT scan findings | MAS | COVID-19 | P value |
|------------------------|-----|----------|---------|
| GGOs, n (%) | 6 (60) | 47 (100) | 0.028 |
| Apical, n (%) | 3 (30) | 31 (65.6) | 0.006 |
| Middle, n (%) | 6 (60) | 42 (89.3) | 0.149 |
| Basal, n (%) | 5 (50) | 45 (95.7) | 0.022 |
| Bilateral, n (%) | 5 (50) | 46 (97.8) | 0.009 |
| Peripheral, n (%) | 5 (50) | 45 (95.7) | 0.014 |
| Extension of GGOs, mean±SD (cm^3) | 1295.96±572.36 | 1529.80±448.13 | 0.336 |
| Extension of GGOs, mean±SD (cm^3) | 39.39±16.19 | 35.80±12.59 | 0.561 |
| Parenchymal consolidation, n (%) | 8 (80) | 29 (61.7) | 0.399 |
| Apical, n (%) | 0 (0) | 11 (23.4) | 0.005 |
| Middle, n (%) | 6 (60) | 19 (40.4) | 0.429 |
| Basal, n (%) | 7 (70) | 23 (48.3) | 0.355 |
| Bilateral, n (%) | 4 (40) | 23 (48.3) | 0.867 |
| Peripheral, n (%) | 2 (20) | 20 (42.5) | 0.999 |
| Extension of consolidation, mean±SD (cm^3) | 227.26±65.91 | 353.31±122.19 | 0.014 |
| Extension of consolidation, mean±SD (cm^3) | 7.15±3.14 | 8.43±4.43 | 0.477 |
| Septal thickening, n (%) | 7 (70) | 39 (82.9) | 0.655 |
| Intralobular, n (%) | 6 (60) | 27 (57.4) | 0.999 |
| Interlobular, n (%) | 7 (70) | 38 (80.8) | 0.759 |
| Bronchovascular thickening, n (%) | 4 (40) | 23 (48.3) | 0.867 |
| Traction bronchiectases, n (%) | 1 (10) | 6 (12.8) | 0.999 |
| Pleural effusion, n (%) | 4 (40) | 6 (12.8) | 0.192 |
| Pneumomediastinum, n (%) | 5 (50) | 30 (63.8) | 0.653 |
| Cardiomegaly, n (%) | 3 (30) | 14 (29.8) | 0.999 |

GGO, ground-glass opacity; MAS, macrophage activation syndrome.
parenchymal involvement, after automated segmentation, from the same CT examinations.

Data sources, study size and bias
Data were collected during scheduled examinations for each patient by reviewing the clinical charts. Institutional Picture Archiving and Communication System was searched for available chest CT examinations, which were also screened for image quality. To overcome the issue of MAS rarity, we increased the number of severe COVID-19 patients to a ratio of about 4:1 to improve the power, without a specific sample size estimation. Although this rise is not linear, an equally small number of controls would provide little ability to retrieve possible associations. We minimised the effects of possible biases and missing data by a careful definition of each variable and a relatively simple study design.

Statistical methods
Data were collected, organised and analysed through XLSTAT V.2017 Data Analysis and Statistical Solution for Microsoft Excel V.2017 (Addinsoft, Paris, France). All the results are expressed as mean±SD for quantitative variables and as number and percentage for categorical variables. Student t-test was used to compare means for continuous variables, whereas Fisher exact test was used to compare proportions. Pearson correlation analyses were performed to correlate laboratory abnormalities with lung involvement extension.

RESULTS
Characteristics of assessed patients
Ten patients with MAS (age 56.20±10.58 years, 6 male patients) and 47 patients with COVID-19 (age 66.27±13.98 years, 35 male patients), before starting any immunosuppressive therapy for their conditions, underwent chest CT, which was considered of sufficient quality for AI assessment (online supplementary figure S1). Due to the specific severe pattern of COVID-19 in elderly patients, the matching for age was not reliable. All patients with MAS and COVID-19 showed fever and dyspnoea. Patients with MAS were characterised by lower platelet counts (121.90±36.34 vs 254.53±19.51 10^9/L, p=0.043) and more elevated ferritin levels (4888.83±1131.49 vs 1207.17±171.66 ng/mL, p=0.010), whereas patients with COVID-19 were characterised by lower lymphocyte counts (2.61±0.58 vs 1.02±0.09 10^9/mL, p=0.005) and higher neutrophil numbers (4.08±0.55 vs 8.98±2.32 10^9/mL, p=0.044). Aspartate aminotransferase (148.8±75.2 vs 34.7±13.1 IU/L, p=0.002) and alanine aminotransferase (178.9±77.4 vs 42.4±14.8 IU/L, p=0.001) levels were increased in MAS. D-dimer was increased in both groups. Other laboratory findings are summarised in table 1. Finally, higher values of H-score characterised patients with MAS than patients with severe COVID-19 (201.9±15.3 vs 88.8±48.3, p<0.0001), as detailed in online supplementary table S4.

Chest CT scan results
All 47 patients with COVID-19 showed ground-glass opacities (GGOs), whereas this finding was observed in 60% of patients with MAS (p=0.028). The proportion of basal, bilateral and peripheral distributions of GGOs was significantly higher in patients with COVID-19 than in patients with MAS (95.7% vs 50%, p=0.022; 97.8% vs 50%, p=0.009; and 95.7% vs 50%, p=0.014, respectively). No significant differences were observed in parenchymal consolidations between groups, except for the more frequent apical consolidations in COVID-19 than in MAS (23.4% vs 0%, p=0.005). Other CT findings are summarised in table 2. About 30% of patients in both groups showed cardiomegaly without any sign of infections or myocarditis. By assessing AI-reconstructed images (figure 1), the extent of consolidation was higher in COVID-19 than in MAS (353.31±122.19 vs 227.26±65.91 cm², p=0.014), whereas the extension of GGOs was similar in both diseases.

In MAS, C reactive protein (CRP) directly correlated with GGOs extension (coefficient 0.75, p=0.031). Similarly, in severe COVID-19, CRP directly correlated with GGOs extension (coefficient 0.49, p=0.020), whereas lymphocytes inversely correlated with GGOs extension (coefficient −0.70, p=0.008). No further correlations were retrieved with other laboratory abnormalities and extension of both GGOs and parenchymal consolidations.

Figure 1  Multiparametric chest CT scan analysis of COVID-19 pneumonia (A,A1–A3) and MAS pneumonias (B,B1–B3). Axial CT scans with lung window level show the prevalent peripheral distribution of parenchymal opacities (arrows) in COVID-19 pneumonia (A1) compared with MAS pneumonia (B1). The automated segmentation using the AI software (A2,B2) depicts more clearly GGOs in yellow and dense opacities in red. The quantitative histogram graphic representations (A,B) confirm the higher percentage of parenchymal involvement by GGOs (red frames) in COVID-19 pneumonia with respect to MAS pneumonia, as shown by the volumetric surface rendering (A3,B3). AI, artificial intelligence; GGO, ground-glass opacity; MAS, macrophage activation syndrome.
DISCUSSION
Severe COVID-19 and MAS are challenging disorders characterized by overlapping clinical pictures, and it is still matter of debate if severe COVID-19 is part or not of the HLH spectrum.\(^1\)\(^10\)\(^11\)

Although all patients showed fever and dyspnoea, laboratory differences were retrieved, since MAS patients showed thrombocytopenia, whereas severe COVID-19 patients were characterised by lymphopenia and neutrophilia. During MAS, thrombocytopenia may depend on haemophagocytosis and severe cytokine-mediated inflammation.\(^3\) Differently, COVID-19 is characterised by isolated lymphopenia, since the virus might infect lymphocytes, inducing their apoptosis.\(^1\)\(^2\)\(^3\) Both diseases showed increased ferritin levels, with the highest levels observed in MAS, which maybe related to the magnitude of the hyperinflammation.\(^1\)\(^8\) D-dimer levels were increased in both groups: in MAS, due to disseminated intravascular coagulation; and in severe COVID-19, for pulmonary intravascular coagulopathy and associated right heart strain.\(^19\)\(^20\) All MAS patients achieved H-score diagnostic cut-off (>169) but only 10% of severe COVID-19 patients did it, suggesting the need of further studies to assess its usefulness in severe COVID-19.

AI-reconstructed chest CT images showed that apical, basal, peripheral and bilateral distributions of GGOs were more represented in severe COVID-19 patients. Furthermore, these patients showed more frequent apical consolidations, with a larger extension than in MAS. AI-quantitative assessment of lung involvement permitted to correlate these radiological findings with the specific laboratory abnormalities observed in our patients. In fact, we observed that CRP directly correlated with GGOs extension in both diseases. Furthermore, lymphopenia inversely correlated with GGOs extension in severe COVID-19. These results may suggest the possible predictive role for some specific biomarkers and may help physicians in identifying more severe patients.

Although providing a comprehensive comparison of clinical, laboratory and radiological findings between MAS and severe COVID-19, our study is affected by some limitations due to the single-centre study design and the relatively low number of patients with MAS, which may limit the external validity. However, it must be pointed out that MAS is a rare disease, and to plan large and multicentre studies is very challenging.

In conclusion, our data showed laboratory and AI-radiological differences between MAS and severe COVID-19; the latter did not appear as being part of the HLH spectrum, thus paving the way for further hypotheses to be investigated in future and larger confirmatory studies.

Contributors All the authors met all criteria for authorship in the ICMJE Recommendations, since all authors made substantial contributions to the conception or design of the work, and the acquisition and interpretation of data. All authors contributed to the critical review and revision of the manuscript and approved the final version. All the authors agreed to be accountable for all aspects of the work.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval The local ethics committee (Comitato Etico Azienda Sanitaria Locale 1 Avezzano/Sulmona/L’Aquila, L’Aquila, Italy; protocol number 0095184/20) approved the study, which was performed according to good clinical practice guidelines and the Declaration of Helsinki.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

ORCID iDs
Onorina Berarducci http://orcid.org/0000-0002-2808-1581
Francesco Carubbi http://orcid.org/0000-0003-1958-5136
Paola Di Benedetto http://orcid.org/0000-0003-2927-8703
Roberto Giacomelli http://orcid.org/0000-0003-0670-9638

REFERENCES
1 McGonagle D, Sharif K, O’Regan A, et al. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. *Autoimmun Rev* 2020;19:102537.
2 Seguin A, Galicier L, Boutboul D, et al. Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis. *Chest* 2016;149:1294–301.
3 Saper V, Chen G, Deutsch GH, et al. Emergent high fatality lung disease in systemic juvenile arthritis. *Ann Rheum Dis* 2019;78:1722–31.
4 Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, et al. Adult haemophagocytic syndrome. *Lancer* 2014;383:1503–16.
5 Ruscitti P, Iacono D, Ciccia F, et al. Macroage activation syndrome in patients affected by adult-onset still disease: analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in Reumatologia clinica E Sperimentale cohort. *J Rheumatol* 2018;45:864–72.
6 Schulert GS, Yasin S, Carey B, et al. Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors. *Arthritis Rheumatol* 2019;71:1943–54.
7 Ruscitti P, Berarducci O, Iacono D, et al. Parenchymal lung disease in adult onset still’s disease: an emergent marker of disease severity-characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia clinica E Sperimentale (GIR RCS) cohort of patients. *Arthritis Res Ther* 2020;22:151.
8 Neri E, Miele V, Coppola F, et al. Use of CT and artificial intelligence in suspected or COVID-19 positive patients: statement of the Italian Society of medical and interventional radiology. *Radiol Med* 2020;125:505–8.
9 Hosny A, Parmar C, Quackenbush J, et al. Artificial intelligence in radiology. *Nat Rev Cancer* 2018;18:500–10.
10 Cron RJ, Chatham WW. The rheumatologist’s role in COVID-19. *J Rheumatol* 2020;47:639–42.
11 Ruscitti P, Berarducci O, Iacono D, et al. Cytokine storm syndrome in severe COVID-19. *Autoimmun Rev* 2020;19:102562.
12 Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HSscore, a score for the diagnosis of reactive hemophagocytic syndrome. *Arthritis Rheumatol* 2014;66:2613–20.
13 Yamaguchi M, Ohta A, Tsumematsu T, et al. Preliminary criteria for classification of adult still’s disease. *J Rheumatol* 1992;19:424–30.
14 Cush JJ, Medsger TA, Christy WC, et al. Adult-Onset still’s disease. clinical course and outcome. *Arthritis Rheum* 1987;30:186–94.
15 Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. *Radiology* 2008;246:697–722.
16 Grimes DA, Schulz KE. Compared to what? Finding controls for case-control studies. *Lancet* 2005;365:1429–33.
17 Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. *Signal Transduct Target Ther* 2020;5:33.
18 Ruscitti P, Berarducci O, Di Benedetto P, et al. Severe COVID-19, another piece in the puzzle of the hyperinflammatory syndrome. An immunomodulatory perspective to alleviate the storm. *Front Immunol* 2020;11:1130.
19 Fox SE, Akmatbekov A, Harbert J, et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. *Lancet Respir Med* 2020;8:681–6.
20 McGonagle D, O’Donnell JS, Sharif K, et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. *Lancet Rheumatol* 2020;2:e437–45.